A novel blood proteomic signature for prostate cancer

Ammara Muazzam, Matt Spick, Olivier N. F. Cexus, Bethany Geary, Fowz Azhar, Hardev Pandha, Agnieszka Michael, Rachel Reed, Sarah Lennon, Lee A. Gethings, Robert S. Plumb, Anthony D. Whetton, Nophar Geifman (Lead / Corresponding author), Paul A. Townsend (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
68 Downloads (Pure)


Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.

Original languageEnglish
Article number1051
Number of pages17
Issue number4
Publication statusPublished - 7 Feb 2023


  • prostate cancer
  • clinical onset
  • biomarkers
  • proteomics
  • complement cascade

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A novel blood proteomic signature for prostate cancer'. Together they form a unique fingerprint.

Cite this